慢性肾脏病——其发展进程如何，我们能做什么以及预期会怎样？
Chronic Kidney Disease-How Does It Go, and What Can We Do and Expect?
作者信息
Chang Li-Yun, Chang Jer-Ming
机构信息
Division of Nephrology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807377, Taiwan.
School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807377, Taiwan.
出版信息
Biomedicines. 2023 Mar 22;11(3):977. doi: 10.3390/biomedicines11030977.
Abstract
Chronic kidney disease (CKD), as a worldwide threat to public health, is a key determinant of poor health outcomes, but the severity of the problem is probably not fully appreciated [...].
摘要
慢性肾脏病（CKD）作为一种全球范围内对公众健康的威胁，是健康不良结局的关键决定因素，但该问题的严重程度可能尚未得到充分认识[……]
相似文献
1
Chronic Kidney Disease-How Does It Go, and What Can We Do and Expect?慢性肾脏病——其发展进程如何，我们能做什么以及预期会怎样？
Biomedicines. 2023 Mar 22;11(3):977. doi: 10.3390/biomedicines11030977.
2
Need for chronic kidney disease prevention programs in disadvantaged populations.弱势群体中慢性肾脏病预防项目的必要性。
Clin Nephrol. 2015;83(7 Suppl 1):42-8. doi: 10.5414/cnp83s042.
3
Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes.慢性肾脏病作为一个全球公共卫生问题：应对方法与倡议——改善全球肾脏病预后组织的立场声明
Kidney Int. 2007 Aug;72(3):247-59. doi: 10.1038/sj.ki.5002343. Epub 2007 Jun 13.
4
Clinical application of antibody microarray in chronic kidney disease: How far to go?抗体微阵列在慢性肾脏病中的临床应用：路在何方？
Proteomics Clin Appl. 2008 Jul;2(7-8):989-96. doi: 10.1002/prca.200780134. Epub 2008 Jul 10.
5
Integrative Bioinformatics Analysis Provides Insight into the Molecular Mechanisms of Chronic Kidney Disease.整合生物信息学分析为深入了解慢性肾脏病的分子机制提供了线索。
Kidney Blood Press Res. 2018;43(2):568-581. doi: 10.1159/000488830. Epub 2018 Apr 6.
6
Reducing major risk factors for chronic kidney disease.降低慢性肾脏病的主要风险因素。
Kidney Int Suppl (2011). 2017 Oct;7(2):71-87. doi: 10.1016/j.kisu.2017.07.003. Epub 2017 Sep 20.
7
The burden of kidney disease: improving global outcomes.肾脏疾病负担：改善全球预后。
Kidney Int. 2004 Oct;66(4):1310-4. doi: 10.1111/j.1523-1755.2004.00894.x.
8
Birth Weight and Susceptibility to Chronic Kidney Disease.出生体重与慢性肾脏病易感性。
Saudi J Kidney Dis Transpl. 2020 Jul-Aug;31(4):717-726. doi: 10.4103/1319-2442.292305.
10
Chronic kidney disease emerging trends in children and what to do about it.儿童慢性肾脏病的新趋势及其应对措施。
J Natl Med Assoc. 2022 Jun;114(3S2):S50-S55. doi: 10.1016/j.jnma.2022.05.002. Epub 2022 May 31.
引用本文的文献
1
Health Literacy and Emotional Management in Patients on Renal Replacement Therapy: A Mixed-Method Study Protocol.肾替代治疗患者的健康素养与情绪管理：一项混合方法研究方案
Healthcare (Basel). 2025 May 2;13(9):1048. doi: 10.3390/healthcare13091048.
本文引用的文献
1
A small erythropoietin derived non-hematopoietic peptide reduces cardiac inflammation, attenuates age associated declines in heart function and prolongs healthspan.一种源自促红细胞生成素的小型非造血肽可减轻心脏炎症，减轻与年龄相关的心脏功能衰退，并延长健康寿命。
Front Cardiovasc Med. 2023 Jan 18;9:1096887. doi: 10.3389/fcvm.2022.1096887. eCollection 2022.
2
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.KDIGO 2022慢性肾脏病糖尿病管理临床实践指南
Kidney Int. 2022 Nov;102(5S):S1-S127. doi: 10.1016/j.kint.2022.06.008.
3
Preventive Effects of Mixture against Chronic Kidney Disease Progression through Enhancement of Beneficial Bacteria and Downregulation of Gut-Derived Uremic Toxins.通过增强有益菌和下调肠道来源尿毒症毒素来预防混合制剂对慢性肾脏病进展的影响。
J Agric Food Chem. 2021 Jul 7;69(26):7353-7366. doi: 10.1021/acs.jafc.1c01547. Epub 2021 Jun 25.
4
6. Glycemic Targets: .6. 血糖目标： 。
Diabetes Care. 2019 Jan;42(Suppl 1):S61-S70. doi: 10.2337/dc19-S006.
5
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.SGLT2 抑制剂用于 2 型糖尿病的心血管和肾脏结局的一级和二级预防：心血管结局试验的系统评价和荟萃分析。
Lancet. 2019 Jan 5;393(10166):31-39. doi: 10.1016/S0140-6736(18)32590-X. Epub 2018 Nov 10.
6
Autosomal dominant tubulointerstitial kidney disease-UMOD is the most frequent non polycystic genetic kidney disease.常染色体显性遗传性肾小管间质性肾病- UMOD 是最常见的非多囊性遗传性肾脏疾病。
BMC Nephrol. 2018 Oct 30;19(1):301. doi: 10.1186/s12882-018-1107-y.
7
Impacts of Indoxyl Sulfate and p-Cresol Sulfate on Chronic Kidney Disease and Mitigating Effects of AST-120.对慢性肾脏病的影响以及 AST-120 的缓解作用。
Toxins (Basel). 2018 Sep 11;10(9):367. doi: 10.3390/toxins10090367.
8
Anemia modifies the prognostic value of glycated hemoglobin in patients with diabetic chronic kidney disease.贫血改变了糖尿病慢性肾脏病患者糖化血红蛋白的预后价值。
PLoS One. 2018 Jun 22;13(6):e0199378. doi: 10.1371/journal.pone.0199378. eCollection 2018.
9
Glycated Hemoglobin and Outcomes in Patients with Advanced Diabetic Chronic Kidney Disease.晚期糖尿病慢性肾病患者的糖化血红蛋白与预后
Sci Rep. 2016 Jan 28;6:20028. doi: 10.1038/srep20028.
10
Chronic kidney disease: a research and public health priority.慢性肾脏病：一项研究和公共卫生重点事项。
Nephrol Dial Transplant. 2012 Oct;27 Suppl 3:iii19-26. doi: 10.1093/ndt/gfs284. Epub 2012 Jul 3.
Zotero 插件